TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01748630
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00661596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02664103
Drug: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT01056965
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.
Study: NCT00625443
Drug: Blinded (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months
Study: NCT04274114
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder
Study: NCT00194753
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 mg/m2 IV weekly x 12
Study: NCT00194753
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/m2 PO daily for 12 weeks
Study: NCT03861936
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.
Study: NCT04530903
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nacl 0.9% (0.5ml) per injection site
Study: NCT01725698
Drug: Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01437501
Drug: placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of dilute pineapple and lime juice daily for 84 days.
Study: NCT01707420
Drug: liquid placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the liquid placebo will receive an identical appearing liquid placebo of 0.4mL/kg.
Study: NCT03124420
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
Study: NCT01974648
Drug: propofol and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01156870
Drug: SAR566658
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study: NCT02036242
Drug: Sufentanil (Opioid plus local anesthetic)
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil combined with 0.125% ropivacaine, 10-15 ml every 1h during labor delivery
Study: NCT03589495
Drug: N Acetyl L Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg n acetyl cysteine dissolved in dextrose5%
Study: NCT01966328
Drug: 36% Resolvine Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36% Resolvine Intravitreal Injection
Study: NCT01966328
Drug: 9% Resolvine Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9% Resolvine Intravitreal Injection
Study: NCT01033552
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.
Study: NCT01471015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old
Study: NCT02576444
Drug: AZD2281
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
Study: NCT02576444
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered AZD5363 at 640 mg twice daily for two days on/five days off (2/7) schedule. Two (2) 200 mg tablets and three (3) 80 mg tablets should be taken twice daily.
Study: NCT02576444
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended dose will be available no earlier than March 2016.
Study: NCT02576444
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered AZD6738 at 160 mg daily for days 1-7 of a 28-day cycle (7/28) schedule. AZD6738 is available as 100, 20, and 10 mg tablets. Tablets should be taken daily.
Study: NCT01256684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal suppository
Study: NCT00669942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to AIN457
Study: NCT03586700
Drug: Placebo Xiao zhong fang granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Made of starch,dextrin and edible pigment from Dongzhimen Hospital of Beijing university of chinese medicine.
Study: NCT00946166
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg daily in the evening for a maximum of 14 days
Study: NCT00946166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
Study: NCT02996682
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet administered orally once daily
Study: NCT02246920
Drug: Flonase®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg/actuation Nasal Spray
Study: NCT02246920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive Nasal Spray
Study: NCT02167620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
Study: NCT00086996
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.
Study: NCT02266264
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
Study: NCT00034684
Drug: Farnesyl Protein Transferase Inhibitor
Normalized name: farnesyl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00612170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg oral tablet once a day dosing
Study: NCT00864981
Drug: WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03366675
Drug: AZD2811
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2811 100mg/vial
Study: NCT01789905
Drug: Tigecycline (Tygacil)
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
Study: NCT01726205
Drug: Placebo drug, normal saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00492960
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatin capsules
Study: NCT00003674
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01364194
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
Study: NCT00378131
Drug: RC-1291
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00378131
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01054586
Drug: Intervention A Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV subjects with HBV or HCV co-infection but normal hepatic function, defined by receipt of FPV 700mg BID/RTV 100mg BID and a baseline AST-platelet ratio index (APRI) score of \<2.0.
Study: NCT01054586
Drug: Intervention B Reduced Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV subjects with mild hepatic impairment, defined by receipt of the recommended reduced FPV/RTV dose (700mg BID/100mg QD).
Study: NCT01054586
Drug: Intervention C
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV subjects with moderate hepatic impairment, defined by receipt of FPV 450mg BID/RTV 100mg QD.
Study: NCT01960569
Drug: active product ( Thrombexx) assigned to arm 1
Normalized name: collagen,activated Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete
Study: NCT03702894
Drug: Clavamox
Normalized name: Clavamox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clavamox, Film-coated Tablets, 875 mg + 125 mg, manufactured by Pharmtechnology LLC, Belarus
Study: NCT03702894
Drug: Augmentin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentin®, Film-coated Tablets, 875 mg + 125 mg, marketed by GlaxoSmithKline Trading CJSC, Russia
Study: NCT02608788
Drug: S.L.®
Normalized name: Sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5mg/ml Benzydamine hydrochloride, S.L.® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Study: NCT02608788
Drug: Difflam Forte ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0mg/ml Benzydamine hydrochloride ,  Difflam Forte ® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Study: NCT02608788
Drug: Acular®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5％ Ketorolac Tromethamine ,  Acular®  spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Study: NCT02608788
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Study: NCT02336854
Drug: Tacrobell tab. 2mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02336854
Drug: Prograf cap. 2mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00702195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of placebo (administered under protocol 38805)
Study: NCT00702195
Drug: recFSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU recFSH daily (reference group administered under protocol 38807)
Study: NCT00724477
Drug: INEGY
Normalized name: Ezetimibe/Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks
Study: NCT02409290
Drug: Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Locally-used WHO-approved MDR-TB regimen
Study: NCT02409290
Drug: Kanamycin
Normalized name: Kanamycin
DrugBank: Kanamycin (DB01172)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
Study: NCT03625687
Drug: Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks of direct acting antiviral treatment based on clinical indication (either Mavyret or Epclusa)
Study: NCT04553705
Drug: Omega 3/Nigella Sativa Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone
Study: NCT04553705
Drug: Omega 3/Nigella Sativa Oil/Indian Costus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Indian Costus supplements
Study: NCT04553705
Drug: Omega 3/Nigella Sativa Oil/Anise seed capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Anise seed supplementation (450mg anise seed)
Study: NCT01396226
Drug: AZD2927
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of AZD2927 administered as an iv infusion
Study: NCT01396226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of placebo administered as an iv infusion
Study: NCT01936636
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01269762
Drug: LipoCol Forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of one, two and four 600 mg red yeast rice capsules (LipoCol Forte) Multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days
Study: NCT04038710
Drug: Triple combination therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.
Study: NCT02419456
Drug: MK-2048A IVR (Low Dose)
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.
Study: NCT02419456
Drug: MK-2048A IVR (Original Dose)
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
Study: NCT01698476
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01123265
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.
Study: NCT01123265
Drug: Anti-TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF to be administered per standard of care within the practice.
Study: NCT01250340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cp day for 30 days
Study: NCT04521023
Drug: Cantabell Tab
Normalized name: ZINC OXIDE 200 mg in 1 mL TOPICAL LOTION [CannaCell Sun Buddy Facial SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to experimental group are treated with Cantabell Tab
Study: NCT00318461
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride placebo 1 mg and 2 mg tablets
Study: NCT00318461
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo 1-3 mL for s.c. (under the skin) injection
Study: NCT04772105
Drug: 2.5mg of BAT5906
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 2.5mg of BAT5906
Study: NCT04772105
Drug: 4.0mg of BAT5906
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 4.0mg of BAT5906
Study: NCT00617305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ambrisentan was administered orally once daily.
Study: NCT04207801
Drug: AUR101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitor of RORγ
Study: NCT04207801
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Placebo of AUR101 tablet
Study: NCT02615847
Drug: Memantinhydrochlorid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.~The study drug will be taken once a day per os, during 12 month.
Study: NCT00715702
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral single dose
Study: NCT03484091
Drug: Hyruan-One
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose intra-articular injection
Study: NCT03484091
Drug: Hylan G-F 20
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose intra-articular injection
Study: NCT03484091
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose intra-articular injection
Study: NCT00115726
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.
Study: NCT02735122
Drug: acetaminophen Tablet
Normalized name: Acetaminophen Tablets
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 test acetaminophen 500 mg tablets
Study: NCT02735122
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo tablets
Study: NCT02735122
Drug: Placebo Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo caplets
Study: NCT02735122
Drug: Placebo Liquid-filled capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo Liquid-filled capsules
Study: NCT00096798
Drug: Ethyl-eicosapentanoic acid (ethyl-EPA)
Normalized name: Eicosapentaenoic acid ethyl ester
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02785003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
Study: NCT02785003
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
Study: NCT02785003
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment.
Study: NCT02305095
Drug: FDC I/H
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
Study: NCT02833389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: UTTR1147A matching placebo will be administered SC.
Study: NCT02833389
Drug: UTTR1147A
Approvals — FDA: no, EMA: no, PMDA: no
Description: UTTR1147A will be administered SC.
Study: NCT01537861
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01940471
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tablet administered orally once daily
Study: NCT01940471
Drug: TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT01532141
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BIA 9-1067 (single-dose)
Study: NCT01940471
Drug: TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT00864097
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral diclofenac SR 75 mg BID for 32 weeks
Study: NCT01622504
Drug: MVP005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg single dose administered intranasally
Study: NCT03368118
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive ABX464 given at 50 mg o.d for an overall period of 48 months.
Study: NCT00698230
Drug: INCB013739
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB013739 5 mg QD tablet
Study: NCT00698230
Drug: INCB013739
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB013739 15 mg QD tablet
Study: NCT00698230
Drug: INCB013739
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB013739 50 mg QD tablet
Study: NCT00698230
Drug: INCB013739
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB013739 100 mg QD tablet
Study: NCT00698230
Drug: INCB013739
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB013739 200 mg QD
Study: NCT00698230
Drug: Placebo comparator matching INCB013739
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally once daily tablet
Study: NCT01622504
Drug: MVP005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg single dose administered intranasally
Study: NCT01033565
Drug: Natrol
Normalized name: Natrol SAMe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
Study: NCT02803528
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodentine is going to be used as the direct pulp capping material
Study: NCT01003002
Drug: Levodopa (delivered intravenously)
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
Study: NCT02048618
Drug: GLPG0634
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral tablet, intake once daily for 20 weeks
Study: NCT02048618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral tablets, intake once daily for 20 weeks
Study: NCT01998217
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.
Study: NCT01998217
Drug: Flurbiprofen and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.
Study: NCT00815763
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion placebo once a day and continued for 14 day